Indaptus Therapeutics, Inc. (INDP)
NASDAQ: INDP · Real-Time Price · USD
0.5150
-0.0349 (-6.35%)
At close: Apr 1, 2025, 4:00 PM
0.5580
+0.0429 (8.34%)
After-hours: Apr 1, 2025, 4:38 PM EDT
Indaptus Therapeutics Employees
Indaptus Therapeutics had 7 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
7
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,146,004
Market Cap
7.43M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 7 | 0 | - |
Dec 31, 2023 | 7 | 1 | 16.67% |
Dec 31, 2022 | 6 | 1 | 20.00% |
Dec 31, 2021 | 5 | 3 | 150.00% |
Dec 31, 2020 | 2 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
INDP News
- 7 days ago - Indaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 Summit - GlobeNewsWire
- 12 days ago - Indaptus Therapeutics Reports New Data Demonstrating Successful Broad Immune System Activation in Weekly Dosing Trial of Decoy20 - GlobeNewsWire
- 14 days ago - Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab - GlobeNewsWire
- 19 days ago - Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 20 days ago - Registration Is Now Open For Tribe Public's Webinar Event “Keys To The Kingdom: Unlocking The Power Of Your Immune System” Featuring Indaptus Therapeutics' CEO On Monday, March 17, 2025 - GlobeNewsWire
- 4 weeks ago - Indaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening its Intellectual Property for Infectious Disease and Cancer Treatments - GlobeNewsWire
- 5 weeks ago - Indaptus Therapeutics' Chief Scientific Officer Dr. Michael Newman to Present at the 10th Annual Innate Killer Summit - GlobeNewsWire
- 7 weeks ago - Indaptus Therapeutics Receives Approval from Health Canada to Expand Clinical Trial of Decoy20 - GlobeNewsWire